[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100503333":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":29,"locations":37,"responsibleParty":55,"collaborators":33,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":62,"acronym":33,"eligibilityCriteria":63,"healthyVolunteers":60,"sex":64,"minAge":65,"maxAge":33,"enrollmentInfo":66,"targetDuration":33,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":33,"overallStatus":40,"whyStopped":33,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Chinese PLA General Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment group","EXPERIMENTAL","COPL + XPO1 inhibitor (Selinexor, 60 mg, po., d1,8,15)",[13],"Drug: XPO1 inhibitor",[15],{"type":16,"name":17,"description":11,"armGroupLabels":18,"otherNames":19},"DRUG","XPO1 inhibitor",[9],[20],"COPL",[22,26],{"name":23,"affiliation":24,"role":25},"Yu Zhao, Graduate","Chief","PRINCIPAL_INVESTIGATOR",{"name":27,"affiliation":28,"role":25},"Sai Huang, Graduate","Attending doctor",[30,35],{"name":23,"role":31,"phone":32,"phoneExt":33,"email":34},"CONTACT","010-66937232",null,"zhaoyu301@126.com",{"name":27,"role":31,"phone":32,"phoneExt":33,"email":36},"helinahs@qq.com",[38],{"facility":39,"status":40,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"ChinaPLAGH","RECRUITING","Beijing","Haidian","100853","China","CN",{"type":47,"coordinates":48},"Point",[49,50],116.39723,39.9075,{"lat":50,"lon":49},[53,54],{"name":23,"role":31,"phone":32,"phoneExt":33,"email":33},{"name":27,"role":31,"phone":32,"phoneExt":33,"email":33},{"type":25,"investigatorFullName":56,"investigatorTitle":57,"investigatorAffiliation":5,"oldNameTitle":33,"oldOrganization":33},"Yu Zhao","Chief physician","100503333","phase-2-clinical-study-of-xpo1-inhibitor-selinexor-combined-with-copl-in-newly-diagnosed-advanced-nkt-cell-lymphoma-100503333",false,"NCT05833893","Clinical Study of XPO1 Inhibitor Selinexor Combined With COPL in Newly Diagnosed Advanced NK\u002FT-cell Lymphoma","Inclusion Criteria:\n\n* Age≥14 years, male or female;\n* Pathologically confirmed newly diagnosed NK\u002FT cell lymphoma according to WHO classification criteria 2016;\n* At least one measurable lesion, defined as bidimensionally measurable, intranodal lesion \\> 1.5 cm in short axis and extranodal lesion \\> 1.0 cm in short axis;\n* ECOG score 0\\~2;\n* Clinical stage III\\~IV;\n* Normal major organ function, meeting the following definitions: Hematology: WBC ≥ 3.5 x 10 9\u002FL, PLT ≥ 75 x 10 9\u002FL, Hb ≥ 80 g\u002FL; Liver and kidney function: AST and ALT ≤ 3.0 ULN; TBIL ≤ 2.0 mg\u002FdL; CCr ≥ 60 mL\u002Fmin; liver and kidney function impairment caused by tumor compression is not limited by this; Fibrinogen: normal at first cycle\n* Expected survival \\> 6 months\n* Agree to use effective contraception;\n* Understand and voluntarily sign written informed consent\n\nExclusion Criteria:\n\n* Prior allogeneic HCT (allo-HCT)\n* Active autoimmune disease\n* Primary central nervous system lymphoma;\n* Patients with infection which requiring treatment. Could be re-enrollment after infection control;\n* Known history of human immunodeficiency virus (HIV) infection\n* Known hypersensitivity to the study drug or any of its excipients;\n* Presence of other active malignancy requiring treatment that could interfere with this study;\n* Patients with other conditions not suitable for enrollment as judged by the investigator.","ALL","14 Years",{"count":67,"type":68},10,"ESTIMATED","INTERVENTIONAL",[71],"PHASE2","Patients with newly diagnosed, pathologically confirmed NK\u002FT-cell lymphoma of stage III-IV treated with XCOPL regimen. 3 weeks for a cycle, with a total of 6-8 cycles.",[74,75,76],"nk\u002FT-cell Lymphoma","Newly Diagnosed","Advanced Lymphoma","2023-04-18",{"date":79,"type":80},"2023-04-27","ACTUAL",{"date":82,"type":68},"2023-05-01",{"date":84,"type":68},"2026-12-31",{"name":5,"class":6},1]